MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

CDK4 inhibitors (CDK4i) earned Breakthrough Therapy Designation from the FDA last year and are entering phase III clinical trials in several cancers. However, not all tumors respond favorably to these drugs. CDK4 activity is critical for progression through G1 phase and into the mitotic cell cycle....

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Kovatcheva, Marta, Liu, David D., Dickson, Mark A., Klein, Mary E., O'Connor, Rachael, Wilder, Fatima O., Socci, Nicholas D., Tap, William D., Schwartz, Gary K., Singer, Samuel, Crago, Aimee M., Koff, Andrew
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2015
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4480747/
https://ncbi.nlm.nih.gov/pubmed/25803170
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker